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Abstract
Herpes zoster ophthalmicus (HZO) is a reactivation of HZ virus that is latent in ophthalmic division of trigeminal 
ganglion. Patients over 50 years old, premature infant, pregnancy woman, receiving immunosuppressive agents, 
and malignancies are at risk of having HZO. Ocular manifestations of HZ are ectropion, entropion, ectopic eyelash, 
keratitis, conjunctivitis, symblepharon, hypoesthesia, episcleritis, scleritis, scleral atrophy and thinning, uveitis, iris 
atrophy, posterior synechiae, acute retinal necrosis, progressive outer retinal necrosis, retinal detachment, retina 
atrophy, optic neuritis, optic atrophy, and strabismus. Polymerase chain reaction, antigen detection, and antibody 
detection can help to confirm diagnosis. Pharmacology treatments for HZ ophthalmicus are antiviral drugs, 
corticosteroids, analgesics, tricyclic antidepressants, and antiepileptic drug. Non-pharmacology therapies are scleral 
contact lens, phototherapeutic keratectomy, photorefractive keratectomy, and penetrating keratoplasty. There are two 
kinds of vaccination which can be given to patients: Live-attenuated varicella zoster vaccine and recombinant zoster 
vaccine. It is recommended by Centers for Disease Control and Prevention and Food and Drugs Administration to 
use recombinant zoster vaccine by 50 years old.
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Introduction
Varicella zoster virus (VZV) is a double-stranded 
DNA from alpha-herpesvirinae that causes varicella 
as primary infection and herpes zoster (HZ) after 
reactivation. VZV has three phases of infection; primary 
infection, clinical quiescence, and reactivation. During 
the primary infection, VZV is extremely contagious, 
especially in children. Virus spreads by direct contact and 
airborne. It goes to regional lymph nodes to replicate, and 
primary viremia spreads virus and leads to replication 
in liver and spleen. Secondary viremia happens when 
the infected mononuclear cells transfer the virus to skin, 
which causes swelling of epithelial cells, ballooning 
degeneration, and accumulation of tissue fluids result in 
pruritic vesicle formation. The vesicles are mostly on the 
trunk, head, and face. The rash lasts for 5 days. Other 
symptoms are malaise, fever, and fatigue [1], [2].
After the primary infection, VZV stays latent 
in peripheral autonomic ganglia along the entire 
neuroaxis including dorsal root ganglia, cranial nerve 
ganglia, and autonomic ganglia. Individuals with older 
age and impaired cell-mediated immunity are at risk 
of developing HZ [3]. HZ is characterized by severe 
pain vesicles over the area of skin or mucosa along its 
dermatomal distribution [1].
Patients with age over 50, premature 
infants, pregnant woman, HIV infection, using 
immunosuppressive agents, or certain malignancies 
and lymphoproliferative disorders are at risk of HZ 
reactivation [4]. It is all related to decreasing of VZV-
specific cell-mediated immunity. Older age tends to 
have lower cell-mediated immunity [5].
HZ ophthalmicus (HZO) is a reactivation of 
HZ virus that is latent in the ophthalmic division of 
trigeminal sensory ganglion, which is separated into 
nasociliary, frontal, and lacrimal branches. Most of the 
patients with HZO present with keratitis, uveitis, and 
conjunctivitis [6]. Complications of it include glaucoma, 
corneal scarring, and post-herpetic neuralgia (PHN) 
that may affect visual function [7].
Epidemiology
In the United States population, the Centers 
for Disease Control and Prevention (CDC) estimates 
that every year there will be 1 million cases of HZ. 
Other individual studies have varied rates ranging from 
3.2 to 4.2/1000 population per year [3]. In Indonesia, 
there were 2232 herpes zoster patients in 13 training 
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hospitals in 2011–2013 with peak age of HZ around 
45–64 years old about 37.95% of HZ total case. Women 
have a higher incidence of having HZ. Incidence of 
HZO in dermatology and venereology department of 
Prof. Dr. R.D. Kandou Hospital in Manado for 2008–
2013 is 17.41% and has the same incidence for the 
right and left eye, with the highest incidence of age 
about 45–64 years (48%) [4].
HZO
Patient with HZO mostly has fever, malaise, 
headache, and neuropathic pain in the eye before skin 
eruptions happen. Neuropathic pain is described as 
burning, tingling, or shooting type on the dermatome of 
infected nerve [5]. Skin lesions erupt on the dermatome 
of the first division of trigeminal nerve, mostly frontal 
nerve. Hutchinson’s sign is papulovesicular rash at 
the tip, side or root of nose, which is a clinical sign of 
HZO [6]. New lesions keep emerging for 3–5 days, 
starts with erythema, macules, papules, and vesicles. 
In elderly or immunocompromised patients, necrotic 
skin lesions can be found [8]. Skin lesions in zoster can 
get into deep dermis so that the scar can last for a long 
time [6]. There is possibility of absence of cutaneous 
involvement which is called zoster sine herpete [9].
Ocular manifestations of HZO may involve 
eyelid, cornea, conjunctiva, episclera, sclera, uvea, optic 
nerve, oculomotor nerve, trochlear nerve, trigeminal 
nerve, and abducens nerve. About 80% of patients with 
Hutchinson’s sign have ocular manifestations [8].
Skin eruptions on eyelid can provoke cicatricial 
eyelid to ectropion, entropion, or ectopic eyelashes. 
The complications can be exposure keratopathy and 
corneal irritation. Complications can be worsen if there 
are impaired corneal sensation and inadequate tear 
production [6]. HZ lesions are contagious when there 
are erupting lesions and before crusts formed [1]. 
Secondary bacterial cellulitis also occur from Gram-
positive organism [10].
Corneal complications of HZO are punctate 
epithelial keratitis, pseudodendrites ulcers, nummular 
keratitis, endotheliitis, disciform keratitis, epithelial 
keratopathy, neurotrophic keratitis, and exposure 
keratitis [9]. The most often corneal complications 
of HZO are punctate epithelial keratitis and 
pseudodendrites. Both are found to be the earliest 
and transient sign. Punctate epithelial keratitis with 
swollen epithelial cells occurs in response to active 
viral replication. Pseudodendrite is a heap of epithelial 
cells, raised and edematous epithelial lesions with 
negative fluorescein staining because the fluorescein 
gather around the sides of heaped epithelium. The 
differences from dendrite of herpes simplex are smaller 
in size, more superficial ulcer, and no terminal bulb 
[8]. In nummular keratitis, anterior stromal infiltrates 
under Bowman’s layer in response to immunologic 
response of viral infection. Endotheliitis presents with 
diffuse or localized folds of Descemet’s membrane, 
stromal, and epithelial edema. Disciform keratitis 
presents with multiple areas of corneal edema with 
minimal infiltration and intact overlying epithelium [10]. 
Serpiginous keratitis is a peripheral ulcerative keratitis 
with infiltrations and thinning that can cause perforation 
or neovascularization. Epithelial keratopathy presents 
as migrating mucoid plug with variable size and 
location. It is associated with peripheral interstitial 
keratitis and/or chronic anterior uveitis. Pathogenesis 
could be because of low-grade viral replication, immune 
reactions, or neurotrophic mechanism. Neurotrophic 
keratopathy has neuronal axonal damage where VZV 
replicates. Its characteristic is corneal hypoesthesia and 
appear 3 days after onset of rash, follows with epithelial 
cicatrization, then causes corneal abnormalities with 
vascularization and perforation [8].
Conjunctiva is also affected by VZV, it can 
become simple papillary or follicular conjunctivitis 
and pseudomembrane cicatrizing conjunctivitis [8]. 
Afterward, it causes symblepharon and hypoesthesia [9].
Episcleritis and scleritis can occur soon after 
skin eruptions. In scleritis, patient will feel pain and there 
will be diffuse or nodular anterior or even necrotizing. In 
chronic or severe scleritis, there is atrophy and thinning 
of sclera [8].
Uveitis is a granulomatous or non-
granulomatous inflammation of anterior chamber with 
keratic precipitates, posterior synechiae, and stromal 
edema. Trabeculitis, trabecular meshwork blockage by 
cellular debris, hypopyon, pigment or blood, pupillary 
block by posterior synechiae, or extensive peripheral 
anterior synechiae can cause hypertony and glaucoma. 
Ischemic occlusive vasculitis can cause iritis and 
become sectorial iris atrophy and paralytic mydriasis [8].
Varicella zoster causes acute retinal necrosis 
(ARN) and progressive outer retinal necrosis (PORN). 
ARN is diagnosed in the presence of one or more clearly 
defined foci of retinal necrosis in retinal peripheral, 
rapid progression of disease without antiviral treatment 
surrounding peripheral region, occlusive vasculitis with 
arteritis, and inflammation on anterior and posterior 
segment. Persistent setting can cause cystoid macular 
edema, rhegmatogenous retinal detachment, and retina 
atrophy. ARN is mostly found in immunocompetent 
patients and PORN in immunosuppressed patients [10].
Infection on optic nerve causes optic neuritis 
and papillitis, which will lead to optic atrophy. VZV 
vaccination in immunocompromised patient can cause 
optic neuritis in few cases. Additional assessments 
such as MRI of brain and orbit with fat-suppressed 
sequences are needed to evaluate optic nerve changes. 
Polymerase chain reaction (PCR) and serology can be 
obtained on samples of serum and cerebrospinal fluid in 
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optic neuropathy or intraocular fluid in uveitis to confirm 
the diagnosis of HZ [11].
Ophthalmoplegia can be originated from 
neurological or orbital lesions and cause internuclear 
ophthalmoplegia, strabismus, isolated, or combined 
ocular motor cranial nerve palsy and orbital myositis. 
Ptosis and lagophthalmus are also likely to happen 
when cranial nerves are infected. When VZV infects 
oculomotor, trochlear, and abducens nerve, there will be 
paralysis of eye movement. Long-term effect will cause 
strabismus. Patients with ophthalmoplegia needed to 
acquire contrast-enhanced MRI of brain and orbits. MRI 
orbital of patients with proptosis, ptosis, chemosis, and 
ophthalmoplegia will show enlargement of extraocular 
muscle and enhancement of extraocular muscle, orbital 
soft tissue, lacrimal gland, and optic nerve sheath. If 
there are meningeal enhancement, ischemic stroke, or 
vasculopathy, lumbar puncture should be performed to 
confirm VZV infection [11].
Most common complication of HZ is PHN. 
Some authors consider post-herpetic neuralgia if the 
pain persists at least 90 days after the onset or resolution 
of rash [12]. Pain varies from allodynia, electric shock, 
stinging, itching, and burning. Risk of PHN increased 
by older age, extension, and severity of rash and early 
neuralgia and decline sensitivity of skin and cornea. 
Pathogenesis of PHN is not clear yet, it can be caused 
by chronic inflammation in trigeminal pathway after 
acute infection resolved. Low-grade viral replication 
can be happened during chronic inflammation [8].
Diagnosis of HZ is decided based on history, 
clinical, and laboratory test if needed. Laboratory test is 
needed when there is diagnostic uncertainty. Laboratory 
test can be done by PCR, antigen detection, antibody 
detection, and viral culture. PCR as the most sensitive 
method has 95–100% of sensitivity and specificity. The 
sample can be obtained from vesicle fluid, moistened 
swab on dried lesion or lesion crusts, salivary fluid, biopsy, 
cerebrospinal fluid, intraocular fluid, and blood samples. 
Antigen of VZV proteins is detected by direct fluorescent 
antibody (DFA) or immunohistochemistry (IHC). Sensitivity 
and specificity of DFA are 82–98% and 76–94%. IHC has 
100% specificity and 94.9% using anti-glycoprotein E. 
Serology detection of IgM, IgG, and IgA of VZV by ELISA, 
EIA, histochemical staining without IHC, electron, and 
immunogold electron microscopy is recommended for HZ 
ophthalmicus. In viral culture, virus is isolated on human 
diploid lung fibroblast (W-38 or MRC-5) or human retinal 
pigment epithelial cells. Viral culture is needed to know 
drug sensitivity or molecular characterization [13].
Treatment
The aims of HZ treatment are lowering viral 
replication, accelerating healing, limiting severity, 
managing acute pain, and reducing complications. 
Antiviral drugs, corticosteroids, and analgesic are used 
for this treatment. Treatment is recommended started 
within 3 days after rash onset. Encrusted lesions are 
less likely to have benefit of antiviral therapy. Patients 
with HZ need to have extra rest, stay hydrated, and 
eat balanced nutrition foods to improve the immune 
system.8
Acyclovir as the first antiviral drug effective 
against VZV, inhibits viral DNA polymerase to inhibit 
VZV replication. Recommended dose of acyclovir is 800 
mg orally 5 times daily for 7–10 days. Intravenous (IV) 
acyclovir is given only for severe HZO in 10–15 mg/kg 
3 times daily for 7 days. This dosage reduces ocular 
complications such as dendritic keratitis, stromal 
keratitis, uveitis, scleritis, and episcleritis [8].
Recommended doses of other ARV are 
valacyclovir 1000 mg 3 times daily and famciclovir 500 
mg 3 times daily [8]. In uncomplicated case, they will be 
given for 7–10 days [5].
Famciclovir and valacyclovir found to be more 
effective because of better absorption results in higher 
antiviral activity and less dosing frequency. Patients 
taking these drugs need to stay hydrated because 
increased creatinine levels found in poorly hydrated 
patients. Alcohol should be avoided because of the 
diuretic effects and interactions with analgesics [14]. 
Foscarnet can be given as alternative in resistant HZO, 
dosing 40 mg/kg 3 times a day to 100 mg/kg twice a day 
for 14–28 days [9].
In ARN, patient receives acyclovir 10 mg/kg 
every 8 h for 10–14 days, then followed by valacyclovir 
1000 mg orally 3 times a day for 6 months. In PORN, 
patient is given ganciclovir 5 mg/kg IV every 12 h 
and foscarnet 90 mg/kg IV every 12 h and intravitreal 
ganciclovir 2 mg/0.05 mL twice a week and/or intravitreal 
foscarnet 1.2 mg/0.05 mL twice weekly. In optic 
neuropathy patients, IV acyclovir 10–15 mg/kg every 
8 h for 2–3 weeks is recommended [15]. Corticosteroid 
is recommended only for combination with antiviral 
drug. It can reduce the pain and increase the rate of 
cutaneous healing. Dosage of 60 mg/day of systemic 
corticosteroid is recommended to reduce the pain, 
then tapered off for 2 weeks to minimize rebound of 
inflammation [15]. Corticosteroid treatment in cranial 
neuropathy is given for 5 days. Systemic corticosteroids 
are also indicated for facial palsy, cranial polyneuritis, 
and severe inflammatory ocular complications. Topical 
corticosteroids treat disciform keratitis, endotheliitis, 
anterior uveitis, and optic neuropathy [5], [16]. However, 
the use of corticosteroid is controversial because it 
will increase risk of ocular complications, thinning 
and perforation of cornea, secondary glaucoma, and 
reactivated dendriform keratitis [5].
For the treatment of PHN, tricyclic 
antidepressants, antiepileptic drug, and analgesics are 
the first-line therapy. Nortriptyline 25 mg at bedtime 
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can be added up to 75 mg, gabapentin 300–600 mg 3 
times a day, and oxycodone 10–20 mg 2 times a day. 
Applying lidocaine 4% eye drop lessens the pain on the 
eye and forehead in 15 min and persists for 36 h [15].
Non-pharmacologic treatments such as lateral 
tarsorrhaphy or lid traction sutures to correct scarring 
on the lid [14]. Scleral contact lenses may be used in 
patients with corneal scarring and severe neurotrophic 
keratopathy to prevent corneal perforation [15], [17]. 
Phototherapeutic keratectomy and photorefractive 
keratectomy can be successful if ocular surface is 
healthy and normal corneal sensation [17]. Penetrating 
keratoplasty is done for widespread corneal scarring [15].
Prevention
There are two kinds of VZV vaccines available 
worldwide, Zostavax (live-attenuated VZV vaccine/ZVL) 
and Shringlex (recombinant zoster vaccine/RZV). Live 
zoster vaccine has dropped HZ incidence by 51% and 
post-herpetic neuralgia by 66% in immunocompetent 
people with 60 years old and older. However, it will lose 
its effectivity after 10 years of vaccination. Recombinant 
zoster vaccine contains VZV glycoprotein E surface 
antigen conjoint with a novel adjuvant system. A 
clinical trial was made in adults 50 years old and over, 
demonstrated that the efficacy of the vaccine was 
97% in all age groups. Another clinical trial for adults 
70 years old and over showed 90% efficacy. It is still 
effective approximately 85% after 4 years [18] [19].
Dose of ZVL is 19.400 plaque-forming units of 
VZV, injected subcutaneously on deltoid region once. 
ZVL is stored in freezer [20]. Vaccine is given within 30 
min after dissolved. Vaccination should be postponed 
if there is fever over 38.5ºC [19]. Patients have local 
adverse reactions such as erythema, swelling, warmth, 
pruritus, pain, and systemic adverse reactions such as 
HZ, pain, rash, pyrexia, dyspnea, asthenia, headache, 
nausea, and dizziness [21].
CDC recommended ZVL given to 
immunocompetent people 60 years old and older 
and people with chronic illness that has humoral 
immunity affected and those anticipating becoming 
immunocompromised. Meanwhile, Food and Drugs 
Administration (FDA) recommended to people 50 years 
old and older because the incidence of HZ was cut down 
by 70% of people with 50–59 years of age group [18]. 
Patients who are immunocompromised or receiving 
immunosuppression treatment are contraindicated to 
receive vaccination. Immunocompromised patients in 
this context are patients in primary immunodeficiency 
history, leukemia, lymphoma, or other malignant 
neoplasm that affect bone marrow or lymphatic system, 
or AIDS or HIV with CD-4 titer less than 200/mm3 or 
<15% of total lymphocyte, patients who received high 
dose of corticosteroid (≥20 mg/day prednisone or 
equivalent) for 2 weeks or more, using >0.4 mg/kg/
week of methotrexate, >3 mg/kg/day of azathioprine 
or >1.5 mg/kg/day mercaptopurine, treatment 
with adalimumab, infliximab, or etanercept and 
transplantation of hematopoietic stem cell <2 years. 
Pregnancy and active untreated tuberculosis are also 
contraindicated to have vaccine [4].
Patients can be vaccinated after 1 month of 
stopping corticosteroid consumption. Patients who 
receive immunomodulator can be vaccinated after 3 
months receiving immunomodulator [18]. RZV is given 
two doses with 2–6 months apart intramuscularly [22]. It 
is stored in refrigerator between 2°C and 8°C. Vaccine 
can be stored to 6 h after reconstitution [20]. It must 
be disposed if frozen before or after reconstitution [22]. 
There are RZV studies reported local and systemic 
reactions after vaccination. Local reactions such as 
pain, redness and swelling, and systemic reactions 
myalgia, fatigue, headache, shivering, fever, and 
gastrointestinal symptoms [20]. Acute local and 
systemic reactions happen more often in people 50–69 
years of age than in older than 70 years, and systemic 
reactions happened more frequently after the second 
dose than the first dose [22].
FDA and CDC recommended RZV vaccination 
for immunocompetent adults 50 years old or older, 
including people who has been vaccinated with ZVL 
at least 2 months previously. RZV is preferred by 
CDC over ZVL because higher and longer lasting 
efficacy across all age groups. Recommendation 
for immunocompromised patients, pregnant, and 
nursing woman is not known yet because they were 
excluded from the clinical trials. Advisory Committee for 
Immunization Practices and CDC recommend RZV as 
first-line therapy [18].
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